PHOSPHATE exporter XPR1/SLC53A1 is required for the tumorigenicity of epithelial ovarian cancer. Issue 6 (24th April 2022) - Akasu‐Nagayoshi, Yoko
Abstract: Ovarian cancer is the fifth most common cause of cancer‐related death in women. Ovarian clear cell carcinoma (OCCC) is a chemotherapy‐resistant epithelial ovarian cancer with poor prognosis. As a basis for the development of therapeutic agents that could improve the prognosis of OCCC, we performed a screen for proteins critical for the tumorigenicity of OCCC using the CRISPR/Cas9 system. Here we show that knockdown of the phosphate exporter XPR1/SLC53A1 induces the growth arrest and apoptosis of OCCC cells in vitro. Moreover, we show that knockdown of XPR1/SLC53A1 inhibits the proliferation of OCCC cells xenografted into immunocompromised mice. These results suggest that XPR1/SLC53A1 plays a critical role in the tumorigenesis of OCCC cells. We speculate that XPR1/SLC53A1 might be a promising molecular target for the therapeutic treatment of OCCC. Abstract : We attempted to identify novel molecular targets critical for the proliferation and tumorigenicity of ovarian clear cell carcinoma (OCCC) using the CRISPR/Cas9 system. In this study, we have found that the phosphate exporter XPR1/SLC53A1 plays an important role in the proliferation and tumorigenicity of OCCC. Our results suggest that XPR1/SLC53A1 might be a promising molecular target for the therapeutic treatment of OCCC.